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Comorbid medical diseases are highly prevalent in the geriatric population, imposing hard-
ship on healthcare services for demented individuals. Dementia also complicates clinical
care for other co-existing medical conditions. This study investigated the comorbidities
associated with dementia in the elderly population aged 65 years and over in Taiwan.
Methods
We conducted a nationwide, population-based, cross-sectional survey; participants were
selected by computerized random sampling from all 19 Taiwan counties between December
2011 and March 2013. After exclusion of incomplete or erroneous data, 8,456 subjects were
enrolled. Of them, 6,183 were cognitively normal (control group), 1,576 had mild cognitive
impairment (MCI), and 697 had dementia. We collected information about types of comor-
bidities (i.e., vascular risk factors, lung diseases, liver diseases, gastrointestinal diseases,
and cancers), Charlson comorbidity index score, and demographic variables to compare
subjects with normal cognition, MCI, and dementia.
Results
Regardless of the cognitive condition, over 60% of the individuals in each group had at least
one comorbid disease. The proportion of subjects possessing at least three comorbidities
was higher in those with cognitive impairment (MCI 20.9%, dementia 27.3%) than in control
group (15%). Hypertension and diabetes mellitus were the most common comorbidities.
The mean number of comorbidities and Charlson comorbidity index score were greater in
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MCI and dementia groups than in control group. Logistic regression demonstrated that the
comorbidities significantly associated with MCI and dementia were cerebrovascular disease
(OR 3.35, CI 2.62–4.28), cirrhosis (OR 3.29, CI 1.29–8.41), asthma (OR 1.56, CI 1.07–
2.27), and diabetes mellitus (OR 1.24, CI 1.07–1.44).
Conclusion
Multiple medical comorbid diseases are common in older adults, especially in those with
cognitive impairment. Cerebrovascular disease, cirrhosis, asthma, and diabetes mellitus
are important contributors to cognitive deterioration in the elderly. Efforts to lower cumulative
medical burden in the geriatric population may benefit cognitive function.
Introduction
The incidence of dementia increases with age and puts a profound socioeconomic burden on
care-givers and healthcare systems in Taiwan [1,2]. A nationwide, population-based, cross-sec-
tional survey of the Taiwanese population aged 65 years or older between 2011 and 2013 dem-
onstrated that the age-adjusted prevalence of mild cognitive impairment (MCI) was 18.7%,
and that of all-cause dementia was 8.04%; its frequency increases strongly with age, from 3.4%
in people aged 65–69 years to 36.8% in those aged 90 years or older [3]. With the population
aging, the number of people with dementia in Taiwan is estimated to increase substantially,
doubling every 20 years, and is expected to reach 0.32 million by 2030 and to exceed 0.6 mil-
lion by 2050 [4].
Although dementia cannot be cured and ultimately may lead to severe disability and institu-
tionalization, reducing the risk of developing dementia takes on added importance in the
absence of a disease-modifying treatment. Previous studies have highlighted that a number of
non-modifiable risk factors, such as age and apolipoprotein E genotype, were strongly associ-
ated with dementia [5]. Emphasis should be placed on understanding which potentially modifi-
able lifestyle and medical factors might alter the risk of dementia. Identifying these risk factors
that hasten the onset and progression of dementia is crucial for timely medical intervention and
predicting prognosis. Improved knowledge of the comorbidities of highly prevalent chronic
health problems in patients with dementia would facilitate the development of preventive strate-
gies aimed at slowing or avoiding rapid clinical and functional deterioration. Therefore, risk fac-
tor modification and reduction will become a fundamental strategy in clinical practice and a
focus of public health efforts, in view of the increasing longevity of populations worldwide.
Patients with dementia have, on average, 2 to 8 additional chronic comorbid illnesses [6,7].
Comorbidities not only complicate dementia care and decrease health-related quality of life,
but also might reveal shared mechanisms between disorders and provide insight into dementia
pathogenesis. Accumulating evidence has shown that vascular risk factors (VRFs), including
hypertension, diabetes mellitus (DM), hyperlipidemia, and cerebrovascular disease, are associ-
ated with cognitive impairment and dementia [8–11]. Aside from VRFs, several chronic medi-
cal disorders, such as hypertension, chronic heart failure, arrhythmia, and diabetes mellitus,
have been reported to be related to cognitive dysfunction and brain pathology and even to co-
occur in dementia, interacting with each other [12,13].
Similar to Western societies, age, sex, family history of dementia, and apolipoprotein E epsi-
lon 4 allele are proven to be the major risk factors for dementia in Taiwan [14–17]. However,
none of these risk factors can be modified by medical interventions or by individual behavior.
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Until now, there have not been any reports regarding the relationship between concurrent
chronic disorders and developing dementia in the Taiwanese population. To address this issue
and pursue preventive approaches, we conducted the first nationwide, population-based,
cross-sectional survey in Taiwan to investigate the epidemiology and risk factors in dementia
and the association of comorbid illnesses with mild cognitive impairment (MCI) and dementia
among people aged 65 years and older.
Methods
Study design and sampling
This study was a nationwide, population-based, cross-sectional survey with participants enrolled
between December 2011 and March 2013. With the assistance of the Ministry of Health and Wel-
fare of Taiwan and local city governments, our study team obtained the address lists needed. All
participants aged 65 years and older were randomly sampled and recruited to achieve a nationally
representative sample. The details of this study are described elsewhere [3,18]. This study was
approved by the ethics committee at the National Taiwan University Hospital. Permission for
interview and written informed consent were obtained from each elder but if that was not possi-
ble, from the closest responsible adult. In addition, verbal consent was asked from the participant
and the informant when the study was explained verbally at the start.
All the subjects completed the survey using door-to-door screenings [3]. We performed in-
person interviews to collect a brief history focusing on cognitive and functional status, followed
by a structured questionnaire recording demographic data, medical comorbidities, lifestyle habit
factors, and mental tests. The medical comorbid conditions were categorized as vascular risk fac-
tors (i.e., hypertension, DM, cerebrovascular disease, and hyperlipidemia), lung diseases, liver
diseases, gastrointestinal diseases, and cancers. The lifestyle habit factors, including social activ-
ity, regular exercise, smoking, drinking, chewing betel nuts, sleep habits, and marital status, were
recorded based on the definitions [18]. The interview process was performed according to an
operational manual that defines all variables examined in this questionnaire. Logic checks for
inconsistency and auditing were performed by experienced supervisors to ensure the quality and
reliability of the entered data [3]. A medical history was taken to detect any insidious change of
behavior or personality and any mental decline from previous levels of functioning [3].
Diagnostic criteria
The diagnosis for all-cause dementia was based on the core clinical criteria recommended by
the National Institute on Aging-Alzheimer’s Association (NIA-AA). Cognitive and functional
status were determined from the evaluation with the participant or a knowledgeable informant
who had taken care of the people with dementia for more than 10 hours a week and were capa-
ble of detecting insidious changes in behavior, personality, decline in mentality or function at
work, or activities of daily living (ADL). Objective assessments included the Clinical Dementia
Rating Scale (CDR) and the Taiwanese Mini-Mental State Evaluation (T-MMSE). Normal
T-MMSE results were defined as a score >24 in literate elderly people and >13 in illiterate
elderly people [19]. Participants who were compatible with the NIA-AA criteria for all-cause
dementia were those with impairment in 2 or more cognitive domains as well as a decline in
daily functions, whereby the cognitive deficits were sufficient to interfere with independence
of daily living function as a result of abnormality in community affairs or at-home hobbies or
personal care, as assessed by the CDR. Functional status was assessed using the ADL scale and
the instrumental activities of daily living (IADL) scale. MCI was diagnosed, based on the crite-
ria recommended by the NIA-AA, as a change in cognition with impairment in 1 or more cog-
nitive domains but no evidence of impairment in social or occupational functioning as
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assessed by the CDR, ADL, and IADL [20]. An individual was considered cognitively normal
when one had none of the conditions listed in the NIA-AA core clinical criteria for all-cause
dementia and have a CDR score of 0 as well as an education adjusted T-MMSE within normal
limits. People with major depression, other mental disorders, delirium, or other serious physi-
cal problems leading to cognitive or functional status impairment did not fulfill the NIA-AA
criteria for all-cause dementia and MCI and were therefore excluded.
The diagnosis of dementia, particularly difficult cases, was re-examined and discussed by a
consultant panel consisting of four neurologists and one clinical psychologist specialized in the
diagnosis and management of patients with dementia. The sampling process, training of inter-
viewers, home visiting procedure, quality control, and protocol approvals were detailed in our
previous report [3]. All interviews were conducted by well-trained field interviewers with con-
tinuous quality control to achieve necessary quality standards. The inter-rater reliability of
global Clinical Dementia Rating was substantial, with a kappa value of 0.671 [3].
Statistical analysis
Continuous variables are reported as means ± standard deviations. Categorical variables are
represented by frequency or percentage. The Charlson comorbidity index (CCI) and number
of comorbidities were analyzed to determine overall systemic health [21]. In the CCI, dementia
was not taken into account given its presence in the cohort study. Univariate logistic regression
analysis was used to assess the association between all comorbidity variables and MCI or
dementia and to calculate crude odds ratio (OR) and its 95% confidence interval (CI). Factors
with a p-value< 0.1 in univariate regression analyses were entered into the multivariate analy-
ses. Multivariate logistic regression model 1 was adjusted for age group, sex, education level,
and body mass index category. Model 2 represented model 1 plus adjustment for lifestyle habit
factors. We calculated the adjusted OR value and its 95% CI for MCI and dementia. All analy-
ses were performed using SAS statistical software (version 9.4) with 2-tailed statistical tests.
Results
Of the 10,571 subjects interviewed, 2,118 were excluded due to incomplete or possibly errone-
ous data, and finally, 8,456 subjects were enrolled. Of the 8,456 participants, 697 (8.2%) ful-
filled the NIA-AA core clinical criteria for all-cause dementia and 1,576 (18.6%) fitted the
criteria for MCI, whereas 6,183 (73.1%) were cognitively normal. Subjects with MCI and
dementia were approximately three years and seven years older than those with normal cogni-
tive function, respectively. Table 1 shows the demographic characteristics of all participants.
Table 2 represents the detailed information of each comorbid illness among the three study
groups. Overall, hypertension and DM were the most common comorbid diseases. The mean
number of comorbidities in the population with MCI (1.51 ± 1.37) and dementia (1.73 ± 1.50)
was significantly higher than that in the population with normal cognition (1.29 ± 1.24).
Among the elderly with normal cognition, 68.3% had one or more comorbidities and 15.6%
possessed at least three. Among the subjects with MCI, 72.4% had at least one comorbid dis-
eases and 20.9% possessed at least three. Among the participants with dementia, 75.5% had
one or more comorbid diseases and 27.3% possessed at least three.
The severity of comorbid diseases was scored according to CCI. The mean CCI score in the
participants with MCI (0.49 ± 0.83) and dementia (0.73 ± 0.96) was significantly greater than
that in the cognitively normal subjects (0.40 ± 0.75). The distribution patterns of the number
of comorbidities and CCI score were different across three study groups (Table 2). The pro-
portion of those with index scores of 1–2, 3–4, and 5 was significantly higher in those with
MCI and dementia than in the normal control group (Table 2).
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Table 3 demonstrates the association between each comorbid illness with MCI and demen-
tia using univariate logistic regression analyses. Associated factors with increased odds for
both MCI and dementia were DM, cerebrovascular disease, lung disease, asthma, and cirrho-
sis. Factors only associated with MCI were hypertension, hyperlipidemia, and gastrointestinal
disease, and only with dementia included tuberculosis, pneumonia, chronic obstructive pul-
monary disease, other lung disease, and cancer.
After adjusting for sex, age, educational level, BMI (model 1, Table 4) or additional lifestyle
habit factors (model 2, Table 4), cerebrovascular disease, cirrhosis, asthma, and DM were still
associated with MCI and dementia. These four risk factors remained consistent with model 1
and model 2 when grouping both MCI and dementia as cognitive impairment.
Table 4 illustrates the adjusted ORs for association with cognitive impairment regarding
comorbidities. In comparison with people without cerebrovascular disease, the adjusted OR of
cognitive impairment was 3.35 (95% CI = 2.62–4.28) in those with cerebrovascular disease.
Compared with people without cirrhosis, the OR in those with cirrhosis was 3.29 (95%
CI = 1.29–8.41). The OR was 1.56 (95% CI = 1.07–2.27) in subjects with asthma, compared
with those without asthma. Compared with people without DM, the OR in people with DM
was 1.24 (95% CI = 1.07–1.44).
Discussion
In this population-based, cross-sectional survey, over 60% of both cognitively preserved and
cognitively impaired older individuals had comorbid medical conditions. Hypertension and
DM were the most frequent comorbid diseases. The magnitude and pattern of comorbidity
Table 1. Demographic data of study participants (n = 8,456).
Normal (n = 6,183) MCI (n = 1,576) Dementia (n = 697)
Continuous variables, n, % Mean SD Mean SD Mean SD
Age 74.85 6.04 77.55 6.70 81.61 7.63
Men 75.42 6.24 78.30 6.86 81.27 7.74
Women 74.25 5.76 77.06 6.55 81.80 7.56
Categorical variables, n, % n % n % n %
Women 3,007 48.63 951 60.34 443 63.56
Age, years
65–74 3,339 54.00 571 36.23 134 19.23
75–84 2,397 38.77 747 47.40 304 43.62
 85 447 7.23 258 16.37 259 37.16
Education, years
0 2,078 33.61 928 58.88 417 59.83
1–6 2,391 38.67 439 27.86 180 25.82
7–12 1,201 19.42 149 9.45 70 10.04
> 12 513 8.30 60 3.81 30 4.30
Body Mass Index (BMI)a
 18 140 2.26 48 3.05 23 3.30
18< BMI 24 2,853 46.14 591 37.50 311 44.62
24< BMI 30 2,299 37.18 525 33.31 178 25.54
> 30 258 4.17 64 4.06 27 3.87
MCI: mild cognitive impairment; SD, standard deviation.
a There were 1,139 subjects with missing data in the BMI category.
https://doi.org/10.1371/journal.pone.0175475.t001
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Table 2. Comorbidities of study participants (n = 8,456).
Normal (n = 6,183) MCI (n = 1,576) Dementia (n = 697)
Categorical variables, n, % n % n % n %
Comorbidities
Vascular risk factor
Hypertension 3,075 49.70 833 52.86 369 52.94
Diabetes mellitus 1,204 19.47 356 22.59 214 30.70
CVD 204 3.30 122 7.74 129 18.51
Hyperlipidemia 1,157 18.71 342 21.70 117 16.79
Lung disease 282 4.56 100 6.35 77 11.05
Tuberculosis 43 0.70 9 0.57 12 1.72
Pneumonia 22 0.36 9 0.57 12 1.72
COPD 16 0.26 7 0.44 6 0.86
Asthma 123 1.99 48 3.05 32 4.59
Benign lung tumor 20 0.32 5 0.32 3 0.43
Other lung diseases 56 0.91 21 1.33 17 2.44
Liver disease 284 4.59 90 5.71 33 4.73
Hepatitis 164 2.65 51 3.24 16 2.30
Cirrhosis 12 0.19 8 0.51 5 0.72
Benign liver tumor 19 0.31 5 0.32 2 0.29
Diagnosed liver disease 73 1.18 21 1.33 10 1.43
Gastrointestinal disease 1,008 16.30 300 19.04 110 15.78
Cancer 280 4.53 59 3.74 53 7.60
Liver cancer 15 0.24 6 0.38 4 0.57
Cervical cancer 20 0.32 6 0.38 2 0.29
Colorectal cancer 55 0.89 10 0.63 11 1.58
Breast cancer 47 0.76 8 0.51 8 1.15
Lung cancer 17 0.27 3 0.19 7 1.00
Gastric cancer 17 0.27 6 0.38 3 0.43
Other cancer 112 1.81 24 1.52 17 2.44
Number of comorbiditiesa
0 1,961 31.7 436 27.6 171 24.5
1 1,938 31.3 451 28.6 184 26.4
2 1,314 21.2 359 22.7 152 21.8
 3 970 15.6 330 20.9 190 27.2
Mean number ± SDb 1.29 ± 1.24 1.51 ± 1.37 1.73 ± 1.50
CCIa
Score 0 4,471 72.31 1043 66.18 357 51.22
Score 1 1,185 19.17 364 23.10 225 32.28
Score 2 382 6.18 123 7.80 82 11.76
Score 3 94 1.52 29 1.84 19 2.73
Score 4 39 0.63 7 0.44 6 0.86
Score 5 12 0.19 10 0.63 8 1.15
Mean score ± SDb 0.40 ± 0.75 0.49 ± 0.83 0.73 ± 0.96
MCI, mild cognitive impairment; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation; CCI, Charlson
comorbidity index.
a p < .0001 by Chi-square test to compare group differences.
b p < .0001 for normal vs. MCI, normal vs. dementia, MCI vs. dementia by ANOVA with Tukey’s post hoc test.
https://doi.org/10.1371/journal.pone.0175475.t002
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strongly involve cognitive impairment, particularly MCI and dementia. We also report evi-
dence that cerebrovascular disease, cirrhosis, asthma, and DM increase the odds for cognitive
impairment.
Higher medical comorbidity not only accelerates functional deterioration leading to the
under-diagnosis and under-treatment of dementia and comorbid illnesses, but also has signifi-
cant implications for poorer self-care, immobility, and polypharmacy [22–24]. Our study showed
the burden of comorbidities is significantly high in older adults with cognitive impairment.
Several studies concerning comorbidities in subjects with cognitive impairment were con-
ducted in Japan [25], Korea [26], the United States [6,7], the United Kingdom [27], France [28],
and Spain [22,29]. The cross-national comparison of detailed information regarding the comor-
bidity and CCI score is presented in Table 5. Taken as a whole, across different countries, the
mean CCI score is 2, but the number and item of common comorbidities vary. Similar to stud-
ies from Japan, Korea, and France, we showed that hypertension, DM, and hyperlipidemia are
the most common comorbidities among subjects with cognitive impairment [25,26,28].
A large body of literature has indicated that several VRFs play common convergent roles in
vascular and neurodegenerative cognitive impairment [30,31]. Our study showed cerebrovas-
cular disease provides the highest risk of MCI and dementia. Cerebrovascular changes, such as
Table 3. Crude ORs of all comorbidities for MCI and dementia using univariate logistic regression analyses.
Variables MCI vs. Normal Dementia vs. Normal
Crude ORs p value 95% CI Crude ORs p value 95% CI
Vascular risk factor
Hypertension 1.13 0.03 1.01–1.27 1.14 0.11 0.97–1.33
Diabetes mellitus 1.21 0.01 1.06–1.38 1.83 < .01 1.52–2.18
Cerebrovascular disease 2.46 < .01 1.95–3.10 6.66 < .01 5.26–8.44
Hyperlipidemia 1.20 0.01 1.05–1.38 0.88 0.21 0.71–1.08
Lung disease 1.42 < .01 1.12–1.79 2.60 < .01 1.99–3.39
Tuberculosis 0.82 0.59 0.40–1.69 2.50 < .01 1.31–4.77
Pneumonia 1.61 0.23 0.74–3.50 4.91 < .01 2.42–9.96
COPD 1.72 0.23 0.71–4.19 3.35 0.01 1.31–8.59
Asthma 1.55 0.01 1.10–2.17 2.37 < .01 1.59–3.53
Benign lung tumor 0.98 0.97 0.37–2.62 1.33 0.64 0.40–4.50
Other lung diseases 1.48 0.13 0.89–2.45 2.74 < .01 1.58–4.74
Liver disease 1.26 0.06 0.99–1.61 1.03 0.87 0.71–1.49
Hepatitis 1.23 0.21 0.89–1.69 0.86 0.58 0.51–1.45
Cirrhosis 2.62 0.03 1.07–6.43 3.72 0.01 1.31–10.58
Benign liver tumor 1.03 0.95 0.39–2.77 0.94 0.93 0.22–4.02
Diagnosed liver disease 1.13 0.62 0.69–1.84 1.22 0.56 0.63–2.37
Gastrointestinal disease 1.21 0.01 1.05–1.39 0.96 0.72 0.78–1.19
Cancer 0.82 0.17 0.62–1.09 1.74 < .01 1.28–2.35
Liver cancer 1.57 0.35 0.61–4.06 2.37 0.13 0.79–7.17
Cervical cancer 1.18 0.73 0.47–2.94 0.89 0.87 0.21–3.80
Colorectal cancer 0.71 0.32 0.36–1.40 1.79 0.08 0.93–3.43
Breast cancer 0.67 0.29 0.31–1.41 1.52 0.28 0.71–3.22
Lung cancer 0.69 0.56 0.20–2.37 3.69 < .01 1.52–8.92
Gastric cancer 1.39 0.49 0.55–3.52 1.57 0.47 0.46–5.37
Other cancer 0.84 0.44 0.54–1.31 1.36 0.25 0.81–2.27
MCI, mild cognitive impairment; COPD, chronic obstructive pulmonary disease; CI, confidence interval; ORs, odds ratios.
https://doi.org/10.1371/journal.pone.0175475.t003
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hemorrhagic infarct, small and large cortical infarct, vasculopathy, and white matter change,
considerably impede trophic coupling in neurovascular units and cause cognitive decline
[32,33].
Table 4. Adjusted ORs for association with cognitive impairment regarding comorbidities.
Model 1 Model 2
Variables ORs (95%CI) p value ORs (95%CI) p value
Comorbidity
Hypertension 0.99 (0.88–1.12) 0.88 0.98 (0.86–1.11) 0.77
Diabetes mellitus 1.27 (1.10–1.46) < .01 1.24 (1.07–1.44) < .01
Cerebrovascular disease 3.66 (2.89–4.64) < .01 3.35 (2.62–4.28) < .01
Hyperlipidemia 0.99 (0.85–1.16) 0.92 0.98 (0.83–1.15) 0.81
Tuberculosis 1.37 (0.74–2.54) 0.31 1.58 (0.84–2.97) 0.16
Pneumonia 1.96 (0.94–4.07) 0.07 1.94 (0.91–4.12) 0.09
Chronic obstructive pulmonary disease 2.17 (0.86–5.43) 0.10 1.88 (0.73–4.87) 0.19
Asthma 1.65 (1.15–2.38) < .01 1.56 (1.07–2.27) 0.02
Other lung diseases 1.58 (0.94–2.65) 0.08 1.54 (0.90–2.63) 0.12
Cirrhosis 4.04 (1.62–10.08) < .01 3.29 (1.29–8.41) 0.01
Gastrointestinal disease 1.00 (0.86–1.18) 0.96 1.01 (0.86–1.19) 0.91
Cancer 1.10 (0.80–1.52) 0.56 0.99 (0.71–1.39) 0.96
Colorectal cancer 0.79 (0.40–1.59) 0.51 0.86 (0.42–1.78) 0.69
Lung cancer 1.40 (0.48–4.11) 0.54 1.36 (0.43–4.27) 0.60
Model 1 indicates model adjusted for age group, gender, education level, and BMI category.
Model 2 indicates model adjusted for age, gender, education level, BMI category, and lifestyle habit factors.
CI: confidence interval; ORs: odds ratios.
https://doi.org/10.1371/journal.pone.0175475.t004
















Cerebrovascular disease, Cirrhosis, Asthma, DM
Japan
(2010)
113 76.1 78.6 – 2.27 Hyperlipidemia, Hypertension
Korea
(2011)
1,786 67 71.4 – – Hypertension, Anemia, DM
US (2002) 15,013 69.8 – – 7.2–8.13 Femoral neck fracture,
Urinary tract infection, Convulsion
US (2006) 107 62.6 75.6 – 2.4 Hypertension, DM






579 72 77.4 1.5 ± 0.9 – Hypertension, Hyperlipidemia
Spain
(2009)
515 70 81 2 ± 1.2 –
Spain
(2014)
3,971 70.1 80.2 – 3.69 Anxiety, Chronic skin ulcers, Parkinson’s disease, Anemia,
Cerebrovascular disease, Cardiac arrhythmia, Thyroid disease
CCI, Charlson comorbidity index; DM, diabetes mellitus;–, not available.
a dementia is not taken into account, given its presence in dementia group.
https://doi.org/10.1371/journal.pone.0175475.t005
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DM was the other VRF associated with increased risk of cognitive impairment in our study.
Disturbance in insulin signaling is the underlying mechanism in DM, and it affects cell growth,
cerebral energy homeostasis, blood-brain barrier integrity, glial function, oxidative stress, and
inflammatory response in the central nervous system [34–36]. Through the common pathway
of insulin resistance and complex metabolic disorders, DM is notably associated with cognitive
decline in the elderly [37].
Cirrhosis was an independent risk factor for cognitive impairment in our study. A wide
range of neurocognitive disorders in cirrhotic patients with or without overt hepatic encepha-
lopathy may be caused by a direct influence of cirrhosis on the nervous system or by sub-
stances or diseases that act on the brain and liver concurrently (e.g., alcohol or Wilson’s
disease) or by hepatitis C virus-induced irreversible neurodegenerative damage [38,39].
As for asthma, our result was in line with the finding that asthma significantly increased the
risk of dementia in one Taiwan nationwide cohort study [40]. In another Taiwan nationwide
longitudinal study, asthma in midlife and in late life increased the risk of cognitive impairment
[41]. The impact of chronic poor pulmonary function on cognition may be the direct conse-
quence of pulmonary limitation and overlapping risk factors in both general and chronic lung
disease populations [42].
Unlike previous reports, hypertension and hyperlipidemia were not associated with cogni-
tive decline in our cohort. The association of hypertension with the risk of dementia is signifi-
cant in middle-aged populations (around 50 years old), rather than in the elderly population
aged 65 years and older [43]. Blood pressure was shown to decrease several years before the
onset of dementia [44]. It might support a nonlinear, age-dependent relationship between
blood pressure and the risk of cognitive decline in the elderly. On the other hand, cholesterol
level was shown to be conversely related to the risk of MCI and dementia in the elderly popula-
tion aged 65 and older [45]. This finding may be due to a decrease in total cholesterol with age,
insufficient nutrition, and decline in BMI several years before onset of dementia [46]. More-
over, in our cohort, most participants with hypertension or hyperlipidemia have been pre-
scribed with antihypertensive or lipid-lowering agents, respectively. This may imply that
medical control of hypertension and hyperlipidemia is beneficial for the risk of developing
dementia.
There are some limitations in this study. First, there is the potential for diagnostic bias and
misclassification of comorbidities because the medical history was taken from the non-
demented participant or based on the medical record documentation or chronically-pre-
scribed drugs, instead of a formal diagnostic assessment by clinicians. Second, the definition of
comorbidity itself is complex. The impact of a given comorbidity on cognition varies in terms
of the duration and severity of the comorbidity before the onset of dementia, pharmacother-
apy, and synergistic effect of other comorbidities. Third, we did not group enrolled partici-
pants into different MCI subtypes and dementia subtypes. Different subtypes of cognitive
impairment may be related to distinct risk factors, thus complicating the identification of
direct relationships. Fourth, as the common limitation of all cross-sectional studies, the cor-
roboration of the causality between comorbidity and cognitive impairment warrants further
investigation in longitudinal studies.
Conclusions
Multiple medical comorbid diseases are common in older adults with cognitive impairment.
Identification and treatment of manageable comorbidities are important to delay the progres-
sion of the disability from dementia. Those with cerebrovascular disease, cirrhosis, asthma,
and diabetes mellitus have higher likelihood of cognitive decline. Due to a constellation and
Comorbidity and dementia in Taiwan
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complexity of comorbidities, greater attention is required to improve a comprehensive, tai-
lored, and patient-centered approach for dementia care.
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